Novavax says that large studies show that its COVID-19 vaccine is very effective
Vaccine maker Novavax said on Monday that its vaccine is very effective against COVID-19 and also prevents mutation in a large late-stage study in the United States and Mexico.
The company said that the overall effectiveness of the vaccine is about 90%, and preliminary data show that it is safe.
Although the U.S. demand for COVID-19 vaccines has fallen sharply, the global demand for more vaccines remains critical. Novavax vaccine is easy to store and transport and is expected to play an important role in promoting vaccine supply in developing countries.
However, this kind of assistance will take several months. The company said it plans to seek authorizations for vaccines in the United States, Europe and elsewhere by the end of September, by which time it will be able to produce up to 100 million doses per month.
Novavax CEO Stanley Erck told the Associated Press: “Many of our first doses of vaccines will be used in low- and middle-income countries, and that is our goal.”
more than 64% of Canadians with More than half of the U.S. population, Have received at least one dose of COVID-19 vaccine. But according to Our World In Data, a tracking organization at the University of Oxford, less than 1% of people in developing countries have had a chance.
Novavax’s research involved nearly 30,000 people 18 years and older in the United States and Mexico. Two-thirds of people received two doses of the vaccine, three weeks apart, and the rest received fake vaccines.
There are 77 COVID-19 cases—14 in the vaccinated group, and the rest are volunteers who received sham injections. No one in the vaccine group had moderate or severe disease, compared to 14 in the placebo group.
The vaccine is equally effective against several variants, including a variant that was first discovered in the UK and dominates in the United States, and high-risk groups including the elderly and people with other health problems.
Mainly minor side effects
The side effects are mostly mild-tenderness and pain at the injection site. Erck said there were no reports of abnormal blood clots or heart problems.
Novavax reported the results in a press release and plans to publish it in a medical journal for review by independent experts. The Maryland-based company previously published the results of small studies conducted in the United Kingdom and South Africa.
The COVID-19 vaccine trains the body to recognize the coronavirus, especially the spike protein that wraps it, and prepares it to fight the virus. The Novavax vaccine is made from a copy of this protein grown in the laboratory. This is different from other vaccines that are now widely used, which include genetic instructions for the body to make its own spike protein.
Novavax vaccine can be stored in a standard refrigerator, making it easier to distribute.
Novavax previously announced that it was postponing production due to supply shortages. The company now expects to reach a monthly output of 100 million doses by the end of September, and a monthly output of 150 million doses by December.
The company promised to supply 110 million doses to the United States next year and 1.1 billion doses to developing countries.
In May of this year, the vaccine alliance Gavi announced that it has signed an agreement to purchase 350 million doses of Novavax vaccine, which is expected to begin delivery in the third quarter. COVAX is a global initiative to provide vaccines to all countries. After its largest Indian supplier suspended exports until the end of the year, it faced a serious shortage of vaccines.
Novavax has been working on developing vaccines for more than three decades, but has not yet brought them to the market. The company’s coronavirus vaccine work is partly funded by the US government.